drugset / Trial / NCT05626348
The Clinical Efficacy of Immunomodulators in RA Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study includes naive patients and csDMARDs-IR RA patients, treated with different regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors for 24 weeks. The disease activity and drug response will be observed. The immune disorder and synovial function will be evaluated at the same time.
Timeline
- Start
- 2021-12-22
- Primary completion
- 2025-06-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | — |
| Subject | Hydroxychloroquine | Small molecule | 200 mg | Oral |
| Subject | Iguratimod | Small molecule | 25 mg | Oral |
| Subject | Leflunomide | Small molecule | 20 mg | Oral |
| Subject | Methotrexate | Small molecule | 10 mg | Oral |